- Home
- LXEO vs RGNX Comparison
LXEO vs RGNX Comparison
Compare LXEO & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXEO | RGNX |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.9M | 418.1M |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LXEO | RGNX |
|---|---|---|
| Price | $5.86 | $10.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $18.44 | ★ $28.75 |
| AVG Volume (30 Days) | ★ 613.5K | 577.6K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.81 | 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | $654,000.00 | ★ $10,393,000.00 |
| Revenue This Year | N/A | $51.21 |
| Revenue Next Year | N/A | $19.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $2.43 | $7.35 |
| 52 Week High | $10.99 | $16.19 |
Technical Indicators
Market Signals| Indicator | LXEO | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 44.86 | 66.86 |
| Support Level | $5.54 | $7.76 |
| Resistance Level | $6.08 | $12.05 |
| Average True Range (ATR) | 0.32 | 0.57 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 23.85 | 85.95 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.